SecBot SecBot
PRESS-RELEASE ·Filed Nov 4, 2026

CRVS

Corvus Pharmaceuticals, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed12d 17h ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

Watch for the full ASH abstract and poster presentation in December 2026 for additional efficacy and safety details. The small sample size (n=3) limits current read-through; expansion to pediatric patients and longer follow-up will be key catalysts.

DirectionNeutral
Confidencemedium
Horizonweeks

soquelitinib

● Neutral Named in this press release
Impact
Phase
Phase 3 (registrational for PTCL); Phase 2 (atopic dermatitis, ALPS); Phase 1b (hidradenitis suppurativa)
Time to market
If the Phase 3 PTCL trial succeeds at its interim futility analysis (Q1 2027) and final readout (estimated primary completion November 2027), a potential NDA submission could occur in 2028, with FDA approval possible in 2029 at the earliest. The atopic dermatitis program is earlier-stage (Phase 2 topline in Q3 2027) and would require additional Phase 3 trials before any regulatory submission.
Next catalyst
None dated

What to watchThe next major binary catalyst is the Phase 3 PTCL interim futility analysis expected in Q1 2027 (roughly 2-5 months away). A positive result would validate soquelitinib's novel ITK-inhibitor mechanism in oncology and support continued enrollment toward the primary completion in late 2027. A futility stop would severely damage the thesis. Separately, the SIERRA1 atopic dermatitis Phase 2 topline data in Q3 2027 will test the drug's potential in a large immunology market. The ASH 2026 poster (Dec 14) on ALPS data (n=3) is an early readout with limited stock-moving potential.

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$10.57
T+0 close · Nov 4, 2026 · via day close
Latest settled
+8.51%
T+5 · $11.47 · next T+20 in 16d
Vs SPY
+9.43%
α at T+5
Latest observation
+4.64%
T+8 · FF3 residual α
  1. T+0 · Nov 4 $10.57entry
  2. T+1 · 12d ago −7.95%α −3.54% · $9.73
  3. T+5 · 6d ago +8.51%α +9.43% · $11.47
  4. T+8 · todayOpen
  5. T+20 · in 16d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Corvus Pharmaceuticals announced positive one-year safety and efficacy data from three ALPS patients in an NIAID-led Phase 2 trial of soquelitinib. All patients discontinued background steroids with no grade 3/4 adverse events. The data will be presented at ASH in December 2026. The results support continued enrollment but are very early (n=3) and from an investigator-initiated trial, not a company-sponsored registrational study.

Key Facts

  • Three ALPS patients completed one year of soquelitinib 200 mg BID with no grade 3/4 adverse events and no treatment interruptions.
  • All three patients discontinued background medications including steroids and reported improvement in ALPS-related systemic symptoms.
  • Data will be presented at ASH Annual Meeting (Dec 12-15, 2026) in New Orleans.
  • There is currently no approved treatment for ALPS, a rare genetic disease.
  • The trial is led by NIAID/NIH, not Corvus; Corvus supplies soquelitinib.
  • Corvus plans to explore longer treatment durations and enroll younger pediatric patients.

Financial Impact

No financial data provided; early-stage data from 3 patients in a rare disease with no approved therapy.

Risk Factors

  • Very small sample size (n=3) limits statistical significance and generalizability.
  • Investigator-initiated trial design; Corvus does not control enrollment or data collection.
  • ALPS is an ultra-rare disease; commercial opportunity is limited even if approved.
  • No timeline for a registrational trial in ALPS; soquelitinib's primary path is PTCL Phase 3.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3395397

Track record

15 reports on CRVS

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +2.61% at T+1 after the Mar 12, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 13, 20263d ago Insider Buy Neutral 3/10 Entry $11.20 Now $10.60 −5.36% settles Feb 12
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $11.37 Now $10.60 −6.77% settles Feb 8
  3. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $10.54 Now $10.60 +0.57% settles Feb 4
  4. Nov 5, 202611d ago Press Release Neutral 4/10 No price data
  5. Nov 4, 202612d ago Press Release Neutral 4/10 Viewing Entry $10.57 Now $10.60 +0.28% settles Feb 2
  6. Sep 30, 20266w ago Press Release Neutral 3/10 Entry $10.93 Now $10.60 −3.02% settles Dec 28
  7. Aug 21, 202612w ago Institutional Cluster Bullish 6/10 Entry $14.46 to $10.60 Now $10.60 −26.69% ▼ −26.69% −23.33% vs SPY
  8. Jul 22, 202616w ago 8-K Neutral 2/10 Entry $13.68 to $9.85 Now $10.60 −22.51% ▼ −28.00% −32.55% vs SPY
  9. Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $11.60 to $14.39 Now $10.60 −8.62% ▲ +24.05% +19.66% vs SPY
  10. May 14, 202626w ago 8-K Bullish 7/10 Entry $13.66 to $13.74 Now $10.60 −22.37% ▲ +0.62% −2.97% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026